Our Mission
The National Bleeding Disorders Foundation (NBDF) Nevada Chapter is dedicated to finding better treatments and cures for inheritable bleeding disorders and to preventing the complications of these disorders through education, advocacy and research.
Our Mission ... In Action
-
We provide year-round events and fundraisers to spread awareness, educate, and generate crucial resources in support of our mission. Hope to see you at our next event!
-
We fight to protect access to quality healthcare and treatments we need to live healthy lives, but we can't do it without your voice. Discover how you and your family can make a big difference by joining our advocacy efforts.
-
We provide mission-focused experiences through education, support, community connections, and fun for those affected by bleeding disorders.
News & Events
CSL Behring, the biopharmaceutical company behind the hemophilia B gene therapy HEMGENIX ® (etranacogene dezaparvovec-drlb), provided an update to the bleeding disorders community regarding the availability of the treatment. In a letter to the hemophilia B community, the company stated that they have “reestablished limited supply in April 2026,” and that they remain committed to actively managing the existing supply.
In a letter sent to healthcare providers, Ferring Pharmaceuticals announced that STIMATE® (desmopressin acetate) nasal spray is expected to be available in the United States beginning October 2026.
Federal:
Medicaid Work Reporting Requirements
